🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524100-29-00
Authorised Phase I

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy

2025-524100-29-00 · tracked via the Priya Life Science EU tracker
Sponsor
Ouro Medicines Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
21/04/2026
Enrollment target
8
Sites
Czechia

Condition studied

Seropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524100-29-00 on CTIS ↗ ← All trials in the EU